Publisher of Iranian Journals and Conference Proceedings

Please waite ..
Publisher of Iranian Journals and Conference Proceedings
Login |Register |Help |عضویت کتابخانه ها
Paper
Title

Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model

مجله علوم پایه پزشکی ایران، دوره: 24، شماره: 4
Year: 1400
COI: JR_IJBMS-24-4_016
Language: EnglishView: 143
This Paper With 8 Page And PDF Format Ready To Download

Buy and Download

با استفاده از پرداخت اینترنتی بسیار سریع و ساده می توانید اصل این Paper را که دارای 8 صفحه است به صورت فایل PDF در اختیار داشته باشید.
آدرس ایمیل خود را در کادر زیر وارد نمایید:

Authors

Sanambar Sadighi - Department of Medical Oncology, Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
Ramezanali Sharifian - Department of Hematology and Oncology, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
Monireh Kazemimanesh - Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran and Université Toulouse III Paul Sabatier, INSERM U۱۰۳۷, Cancer Research Centre of Toulouse (CRCT), Toulouse, France
Ahad Muhammadnejad - Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences
Zahra Shohosseini - Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
Saeid Amanpour - Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences
Samad Muhammadnejad - Gene Therapy Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran

Abstract:

Objective(s): Immune checkpoint expression on tumor-infiltrating lymphocytes (TILs) has a correlation with the outcome of neoadjuvant chemotherapy (NAC) in breast cancer. However, the reciprocal effect of these regimens on the quality and quantity of immune checkpoints has hitherto not been addressed. We aimed to evaluate the impact of three NAC regimens on TILs and immune checkpoints in a murine triple-negative breast cancer model.Materials and Methods: Syngeneic model of locally-advanced breast cancer was established in immunocompetent mice using a ۴T۱ cell line. Tumor-bearing animals were treated with human-equivalent dosages of doxorubicin, paclitaxel, paclitaxel and carboplatin combination, and placebo. Infiltration of CD۳+, CD۸+, and FoxP۳+ cells into the tumor was assessed by immunohistochemistry. Expression of immune checkpoints, including PD-۱, CTLA-۴, and TIM-۳, was evaluated by real-time PCR.Results: Doxorubicin led to a significant (p <۰.۰۱) increase in the percentage of the stromal infiltrating CD۳+ and CD۸+ lymphocytes. Doxorubicin also suppressed significantly (p <۰.۰۵) the relative expression of PD-۱ compared with the placebo. PD-۱ expression was significantly (p <۰.۰۵) lower in the group treated with paclitaxel and carboplatin combination as compared with the placebo. The relative expression of TIM-۳ was significantly (p <۰.۰۵) suppressed in doxorubicin-treated mice in comparison with other interventions.Conclusion: Our findings hypothesize that NAC with doxorubicin may potentiate antitumor immunity not merely by recruitment of TILs, but via down-regulation of PD-۱ and TIM-۳ checkpoints. Carboplatin-containing NAC may suppress PD-۱ as well.

Keywords:

Animal model Breast neoplasms Immune checkpoints Neoadjuvant chemotherapy Tumor , infiltrating , Lymphocytes

Paper COI Code

This Paper COI Code is JR_IJBMS-24-4_016. Also You can use the following address to link to this article. This link is permanent and is used as an article registration confirmation in the Civilica reference:

https://civilica.com/doc/1186925/

How to Cite to This Paper:

If you want to refer to this Paper in your research work, you can simply use the following phrase in the resources section:
Sadighi, Sanambar and Sharifian, Ramezanali and Kazemimanesh, Monireh and Muhammadnejad, Ahad and Shohosseini, Zahra and Amanpour, Saeid and Muhammadnejad, Samad,1400,Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model,https://civilica.com/doc/1186925

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :

  • 1. Denduluri N, Miller K, O’Regan RM. Using a neoadjuvant ...
  • 2. Rapoport BL, Demetriou GS, Moodley SD, Benn CA. When ...
  • 3. Rivera Vargas T, Apetoh L. Danger signals: Chemotherapy enhancers? ...
  • 4. Disis ML, Stanton SE. Triple-negative breast cancer: Immune modulation ...
  • 5. Gooden MJM, De Bock GH, Leffers N, Daemen T, ...
  • 6. Ansell SM, Vonderheide RH. Cellular composition of the tumor ...
  • 7. DeLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The ...
  • 8. Velcheti V, Schalper K. Basic overview of current immunotherapy ...
  • 9. Silverman GJ, Azzouz DF, Mor A. Immune checkpoint inhibitors ...
  • 10. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The ...
  • 11. Melichar B. The biology of tumor-infiltrating Leukocytes in breast ...
  • 12. Lee SY, Ju MK, Jeon HM, Jeong EK, Lee ...
  • 13. Lee H, Lee M, Seo J, Gong G, Lee ...
  • 14. Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf ...
  • 15. Denkert C, Von Minckwitz G, Brase JC, Sinn BV, ...
  • 16. Steenbrugge J, Breyne K, Demeyere K, Wever O De, ...
  • 17. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size ...
  • 18. Arifin WN, Zahiruddin WM. Sample size calculation in animal ...
  • 19. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from ...
  • 20. Vittoria M, Radosevic-robin N, Fineberg S, Eynden G Van ...
  • 21. Jia L, Liu Y, Wang L, Zhu J, Huang ...
  • 22. Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for ...
  • 23. Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, ...
  • 24. Mao Y, Qu Q, Zhang Y, Liu J, Chen ...
  • 25. Dieci M V., Criscitiello C, Goubar A, Viale G, ...
  • 26. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel ...
  • 27. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot ...
  • 28. Liu M, Guo S, Stiles JK. The emerging role ...
  • 29. Hu J, Zhu S, Xia X, Zhang L, Kleinerman ...
  • 30. Wang YJ, Fletcher R, Yu J, Zhang L. Immunogenic ...
  • 31. Zhang Z, Yu X, Wang Z, Wu P, Huang ...
  • 32. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The ...
  • 33. Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi ...
  • 34. Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili ...
  • 35. De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, Steinberger ...
  • 36. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo ...
  • 37. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz ...
  • 38. Kotsakis A, Sarra E, Peraki M, Koukourakis M, Apostolaki ...
  • 39. Zhang L, Dermawan K, Jin M, Liu R, Zheng ...
  • 40. Zhou L, Xu Q, Huang L, Jin J, Zuo ...
  • 41. Lesterhuis WJ, Punt CJ a, Hato S V, Eleveld-trancikova ...
  • 42. Rojkó L, Reiniger L, Téglási V, Fábián K, Pipek ...
  • 43. Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen ...
  • 44. Wang X, Teng F, Kong L, Yu J. PD-L1 ...
  • 45. Ock C-Y, Kim S, Keam B, Kim S, Ahn ...
  • 46. Homma Y, Taniguchi K, Nakazawa M, Matsuyama R, Mori ...
  • 47. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard ...
  • 48. Wang W, Wu L, Zhang J, Wu H, Han ...
  • 49. Shujin A, Corresponding C, Cui S. Immunogenic chemotherapy sensitizes ...
  • 50. Bespalov A, Michel MC, Steckler T. Good research practice ...
  • 51. Xing K, Gu B, Zhang P, Wu X. Dexamethasone ...
  • 52. Geng H, Zhang G-M, Li D, Zhang H, Yuan ...
  • 53. Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A. CTLA-4 ...

Research Info Management

Certificate | Report | من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:

اطلاعات استنادی این Paper را به نرم افزارهای مدیریت اطلاعات علمی و استنادی ارسال نمایید و در تحقیقات خود از آن استفاده نمایید.

Scientometrics

The specifications of the publisher center of this Paper are as follows:
Type of center: علوم پزشکی
Paper count: 9,386
In the scientometrics section of CIVILICA, you can see the scientific ranking of the Iranian academic and research centers based on the statistics of indexed articles.

Share this page

More information about COI

COI stands for "CIVILICA Object Identifier". COI is the unique code assigned to articles of Iranian conferences and journals when indexing on the CIVILICA citation database.

The COI is the national code of documents indexed in CIVILICA and is a unique and permanent code. it can always be cited and tracked and assumed as registration confirmation ID.

Support